A new international study reveals a possible connection between GLP1 receptor agonists—used in drugs like Ozempic—and ...

Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral ...

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists-widely used in blockbuster ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are ...

The results Lilly is reporting for its oral pill come as another big drug company, Pfizer, has decided to discontinue its ...

New research being presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that ...

Once-daily orforglipron was more effective than placebo and just as safe as injectable GLP-1s in patients with diabetes and ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...